In 21 April Lancet Eric Tartour and colleagues from the Hôpital Européen Georges Pompidou, Paris, propose the use of soluble interleukin-2 receptor as a prognostic marker in head and neck cancer. The ...

Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation ...

Research led by Naval Medical University's Changzheng Hospital in China reports that an off-the-shelf cell therapy built from ...

Key takeaways: Rezpegaldesleukin is a first-in-class interleukin-2 receptor agonist that proliferates and activates regulatory T cells. The study reached its target enrollment of 396 patients.

Soluble CD25 is also known as soluble interleukin-2 receptor α. This criterion was included in the HLH-2004 diagnostic criteria but not in the revised 2024 criteria, since cytotoxicity assays ...

Rezpegaldesleukin, an investigational interleukin-pathway agonist, demonstrated efficacy and safety for people with moderate to severe atopic dermatitis, meeting its primary and secondary ...

The use of serum interleukin-2 receptor value for diagnosis of malignant lymphoma. Masanobu Nakata , Takahide Ara , Kanako Shima , Koichiro Minauchi , Shuichi Ota , Kiyotoshi Imai , Teiichi Hirano , ...

A study in the journal Science Immunology now shows how two subsets of one type of immune cell — the CD8 T cell — develop to provide either short-term or long-term immune protection. The study focuses ...

The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials ...